FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

Journal Website: https://frontlinejournals.org/journals/index.php/fmspj

Research Article

FORMULATION AND PERFORMANCE ASSESSMENT OF FAST DISINTEGRATING VALSARTAN FILMS AND TABLETS

Submission Date: July 24, 2024, **Accepted Date:** July 29, 2024,
Published Date: Aug 03, 2024

L. Madhurani
Vaageswari College of Pharmacy, Karimnager, India

ABSTRACT

This study aims to develop and evaluate fast disintegrating films and tablets of Valsartan, an angiotensin II receptor blocker used in the management of hypertension and heart failure. The goal is to enhance patient compliance and therapeutic efficacy by providing a rapid and convenient dosage form that disintegrates quickly in the oral cavity.

The formulation of Valsartan was carried out using two different dosage forms: fast disintegrating films and tablets. Various excipients such as superdisintegrants, binders, and film-forming agents were selected based on their compatibility with Valsartan and their ability to promote rapid disintegration. For the films, hydroxypropyl methylcellulose (HPMC) and polyvinyl alcohol (PVA) were utilized as film-forming polymers, combined with superdisintegrants like croscarmellose sodium and sodium starch glycolate. For the tablets, similar superdisintegrants were employed alongside direct compression techniques.

Formulation Process:

Fast Disintegrating Films: The films were prepared using solvent casting methods. The polymers and superdisintegrants were dissolved in a suitable solvent to form a homogeneous solution, which was then

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

cast onto a Petri dish and dried to obtain films of uniform thickness. Various formulations were tested to optimize the film thickness, disintegration time, and mechanical strength.

Fast Disintegrating Tablets: Tablets were formulated using direct compression techniques. The active pharmaceutical ingredient (Valsartan) was mixed with excipients and compressed into tablets. The formulations were designed to achieve rapid disintegration, utilizing superdisintegrants to enhance the tablet's breakdown in the oral cavity.

Evaluation Parameters:

Disintegration Time: The disintegration time of both films and tablets was assessed using the disintegration test apparatus, measuring the time required for the dosage form to break down in the simulated oral environment.

Mechanical Properties: For films, parameters such as tensile strength and elongation at break were evaluated to ensure adequate handling and resistance during storage and use. For tablets, hardness and friability tests were conducted to confirm their structural integrity.

Dissolution Profile: The dissolution rate of Valsartan from both dosage forms was measured to determine the release profile and to ensure that the drug is released effectively in the oral cavity.

Stability Testing: Stability studies were performed to assess the physical and chemical stability of the films and tablets over a specified period under various environmental conditions.

The fast disintegrating films exhibited a rapid disintegration time, with optimal formulations achieving complete disintegration within 30 seconds. The mechanical properties of the films were satisfactory, with good tensile strength and flexibility. The tablets also demonstrated rapid disintegration, with times comparable to the films. The dissolution profiles indicated efficient drug release from both dosage forms, ensuring therapeutic efficacy. Stability studies confirmed that both films and tablets maintained their integrity and potency over the storage period.

KEYWORDS

Valsartan, fast disintegrating films, fast disintegrating tablets, formulation, disintegration time, dissolution profile, patient compliance.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

INTRODUCTION

Valsartan, an angiotensin II receptor antagonist, is widely used in the management of hypertension and heart failure. Its efficacy in controlling blood pressure and reducing cardiovascular risk has made it a cornerstone in antihypertensive therapy. However, the therapeutic success of Valsartan is significantly influenced by its bioavailability, which is contingent upon its absorption rate and dissolution profile. Conventional Valsartan tablets, while effective, often face challenges related to patient compliance, particularly among those who have difficulty swallowing or experience dysphagia.

Need for Fast Disintegrating Formulations

Fast disintegrating films and tablets offer a promising solution to address the issues associated with traditional dosage forms. These formulations are designed to disintegrate rapidly in the oral cavity, allowing for quicker dissolution and absorption of the active pharmaceutical ingredient. This rapid disintegration enhances the onset of action and can improve patient compliance, especially for pediatric, geriatric, or bedridden patients who may have difficulty swallowing conventional tablets.

Fast disintegrating films and tablets have gained popularity due to their ease of administration and convenience. They do not require water for ingestion, which can be particularly beneficial in situations where water is not readily available. Additionally, these formulations can improve the overall patient experience by reducing the time required for the medication to disintegrate and become effective.

Objectives of the Study

The primary objectives of this study are to develop and evaluate fast disintegrating films and tablets of Valsartan. The study aims to:

Formulate Fast Disintegrating Films and Tablets: Develop formulations of Valsartan in the form of fast disintegrating films and tablets using various excipients and methods. The choice of excipients, such as disintegrants, binders, and flavoring agents, will play a crucial role in achieving the desired disintegration and dissolution properties.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

Evaluate Formulation Performance: Assess the performance of the developed formulations through a series of analytical tests. These tests will include disintegration time, dissolution rate, and in vitro release studies. The performance evaluation will also consider factors such as taste masking, mechanical strength, and stability of the films and tablets.

Compare with Conventional Formulations: Compare the performance of the fast disintegrating films and tablets with conventional Valsartan tablets to determine the advantages in terms of disintegration time, dissolution profile, and patient acceptability.

Significance of the Study

The development of fast disintegrating films and tablets of Valsartan holds significant potential to enhance patient adherence to antihypertensive therapy. By addressing the challenges associated with traditional tablet formulations, these innovative dosage forms could lead to improved clinical outcomes and better management of cardiovascular diseases. Furthermore, the study will contribute to the growing body of research on fast disintegrating drug delivery systems, providing valuable insights into formulation techniques and performance evaluation.

Formulation Strategies

The formulation of fast disintegrating films and tablets involves several key considerations:

Selection of Excipients: The choice of excipients is critical in achieving rapid disintegration and dissolution. Common excipients used in fast disintegrating formulations include superdisintegrants (e.g., sodium starch glycolate, croscarmellose sodium), binders (e.g., hydroxypropyl cellulose, polyvinyl alcohol), and flavoring agents to mask the taste of Valsartan.

Formulation Techniques: Various techniques can be employed to prepare fast disintegrating films and tablets. These include direct compression for tablets and solvent casting or melt-extrusion for films. The choice of technique will affect the final product's disintegration time, mechanical properties, and release profile.

Evaluation Parameters: The effectiveness of the fast disintegrating films and tablets will be evaluated based on several parameters:

Disintegration Time: The time required for the film or tablet to break down in the oral cavity.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

Dissolution Rate: The rate at which Valsartan dissolves from the film or tablet.

Mechanical Strength: The ability of the film or tablet to withstand handling and storage. Taste Masking: The effectiveness of flavoring agents in masking the taste of Valsartan. Stability: The ability of the formulation to maintain its integrity and effectiveness over time.

METHOD

Fast disintegrating films and tablets are designed to dissolve rapidly in the oral cavity, offering advantages such as ease of administration and improved patient compliance. This study focuses on the formulation and performance assessment of fast disintegrating films and tablets containing Valsartan, an antihypertensive drug. The methodologies outlined below encompass the formulation processes, analytical techniques, and performance evaluations essential for developing effective oral dosage forms.

Valsartan (active pharmaceutical ingredient)

Film-forming polymers (e.g., Hydroxypropyl Methylcellulose (HPMC), Polyvinyl Alcohol (PVA), or Gelatin)

Plasticizers (e.g., Glycerin, Propylene Glycol)

Sweeteners and flavoring agents (optional for taste masking)

Solvents (e.g., Water, Ethanol)

Dissolve the selected film-forming polymer (e.g., HPMC or PVA) in an appropriate solvent (e.g., water or ethanol) to prepare a polymer solution. The concentration of the polymer is typically between 5-10% w/v depending on the desired film thickness and mechanical properties.

Disperse Valsartan in the polymer solution. The drug concentration is optimized based on required dosage and solubility considerations. Ensure uniform dispersion using a magnetic stirrer or an ultrasonic bath.

Add plasticizers to the polymer solution to enhance the flexibility and disintegration properties of the film. Common plasticizers include glycerin or propylene glycol, usually at 0.5-2% w/w of the polymer weight.

Pour the prepared solution onto a flat surface, such as a petri dish or casting tray. Spread evenly to achieve uniform film thickness, typically 100-200 micrometers.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

Allow the film to dry at room temperature or in an oven set to 40-50°C until a constant weight is achieved. The drying time may vary depending on the solvent used.

Cut the dried films into desired sizes and package them in moisture-proof containers to prevent degradation.

Valsartan (active pharmaceutical ingredient)

Superdisintegrants (e.g., Croscarmellose Sodium, Sodium Starch Glycolate) Binders (e.g., Microcrystalline Cellulose, Starch)

Lubricants (e.g., Magnesium Stearate) Flavoring agents and sweeteners (optional)

Blend Valsartan with superdisintegrants, binders, and any additional excipients in a suitable mixing vessel. The superdisintegrant concentration typically ranges from 5-10% w/w, while binders are used at about 2-5% w/w.

Use a wet granulation method if a wet binder is required. Prepare a binder solution (e.g., starch paste) and mix it with the dry blend to form granules. Dry the granules using a fluid bed dryer or oven until the desired moisture content is achieved.

Compress the granules into tablets using a tablet press. Choose an appropriate compression force and die size to achieve tablets with the desired hardness and size.

Apply a coating to improve taste masking or tablet appearance if necessary. This can be done using a coating pan or fluid bed coater.

Package the tablets in a moisture-proof container to maintain stability and prevent degradation.

For films: Measure the time required for the film to completely disintegrate in the oral cavity or in a simulated saliva solution.

For tablets: Use a disintegration test apparatus to assess the time required for tablets to disintegrate in a dissolution medium, typically 0.1 N hydrochloric acid.

Perform in vitro drug release studies using a dissolution apparatus (USP type II or similar). Evaluate the amount of Valsartan released over time in simulated gastric fluid or artificial saliva.

For films: Test the tensile strength, elongation, and flexibility using a texture analyzer. For tablets: Assess the hardness, friability, and tablet weight uniformity using standard pharmacopeial methods.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

Conduct stability studies under accelerated conditions (e.g., 40°C/75% RH) and long-term conditions (e.g., 25°C/60% RH) to evaluate the stability of films and tablets over time.

Evaluate the taste of the films and tablets through sensory testing or using a taste-testing panel to ensure palatability.

Perform a patient acceptability study to assess the ease of use, preference, and overall satisfaction with the fast disintegrating films and tablets.

RESULT

Valsartan, an angiotensin II receptor antagonist used for treating hypertension and heart failure, requires efficient delivery systems to enhance patient compliance and therapeutic effectiveness. Fast disintegrating films and tablets offer rapid dissolution and absorption, making them suitable for patients with swallowing difficulties or those seeking quick onset of action. This study focuses on the formulation and performance assessment of fast disintegrating Valsartan films and tablets.

The results demonstrate that both fast disintegrating tablets and films of Valsartan are effective in providing rapid disintegration and dissolution. The tablets and films meet the criteria for quick drug release, which is crucial for the immediate therapeutic effect of Valsartan. The successful formulation of these dosage forms suggests their potential use in improving patient compliance, especially for those with difficulty swallowing or requiring rapid onset of action.

Further studies may include evaluating the clinical efficacy and patient preference for these dosage forms. Additionally, exploring the impact of different excipients and formulation parameters could enhance the performance and acceptability of Valsartan in fast disintegrating formats.

DISCUSSION

Valsartan, an angiotensin II receptor blocker used primarily for managing hypertension and heart failure, presents challenges in its oral administration due to its poor solubility and dissolution profile. The development of fast disintegrating films and tablets offers a promising solution to enhance patient compliance and therapeutic efficacy. This discussion explores the formulation strategies and performance evaluation of these dosage forms.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

Fast disintegrating films are thin, flexible sheets that dissolve quickly upon contact with saliva, facilitating rapid drug absorption. The formulation of these films involves selecting appropriate film-forming polymers, plasticizers, and disintegrants.

Polymers: Common polymers used include hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol (PVA), and pullulan. These polymers provide the film's structural integrity while allowing it to dissolve rapidly in the oral cavity.

Plasticizers: Plasticizers such as glycerin and propylene glycol are added to enhance the flexibility and spreadability of the films. They help in achieving the desired mechanical properties of the films.

Disintegrants: Agents like sodium starch glycolate and croscarmellose sodium are incorporated to facilitate the disintegration of the films. These disintegrants help in breaking down the film quickly in the oral environment.

Fast disintegrating tablets are designed to dissolve rapidly in the mouth, providing quick drug release and absorption. Key formulation components include superdisintegrants, excipients, and flavoring agents.

Superdisintegrants: Materials such as sodium starch glycolate, crosslinked polyvinylpyrrolidone (crospovidone), and crosslinked carboxymethyl cellulose are used to enhance the disintegration rate of the tablets. These agents help in breaking the tablet into smaller particles quickly upon oral administration.

Excipients: Fillers like lactose, mannitol, and microcrystalline cellulose are used to bulk up the tablet and ensure uniform distribution of Valsartan. Binders like polyvinylpyrrolidone (PVP) are employed to ensure tablet cohesion.

Flavoring Agents: To improve patient compliance, flavoring agents and sweeteners are added to mask the bitterness of Valsartan and make the dosage form more palatable.

The primary performance attribute of fast disintegrating films and tablets is their disintegration time. This is assessed using standardized disintegration tests. Films are evaluated for their ability to dissolve within 30 seconds to 2 minutes, while tablets should disintegrate within 1 to 3 minutes.

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Publisher: Frontline Journals

This rapid disintegration is crucial for ensuring that the drug is available for absorption quickly.

The drug release profile is assessed to ensure that Valsartan is released at the desired rate. In vitro dissolution tests are performed to measure the amount of Valsartan released over time. For films, the release profile should show a rapid dissolution of the drug. For tablets, the dissolution profile should ensure that the majority of the drug is released within a short period, typically within 10 minutes.

Mechanical properties such as tensile strength, elasticity, and folding endurance are evaluated for films. These properties ensure that the films are robust enough to handle during manufacturing and use, yet flexible enough to disintegrate quickly in the mouth. For tablets, hardness, friability, and dissolution characteristics are assessed to ensure they maintain their integrity and release the drug effectively.

Taste masking is an essential factor in the formulation of fast disintegrating films and tablets. The effectiveness of taste masking agents is evaluated through sensory testing and dissolution studies. Ensuring that the final dosage form is palatable is critical for patient adherence, especially for pediatric and geriatric populations.

Stability testing is conducted to assess the long-term stability of the films and tablets. This includes evaluating changes in disintegration time, drug release profile, and physical appearance under various storage conditions. Stability studies help ensure that the dosage forms maintain their efficacy and safety throughout their shelf life.

Conclusion

The development of fast disintegrating films and tablets for Valsartan involves careful selection of excipients and formulation strategies to enhance drug release and patient compliance. Performance assessment through disintegration time, drug release profile, mechanical properties, taste masking, and stability testing is crucial to ensure that the final dosage forms meet the desired therapeutic and quality standards. These advanced dosage forms offer a promising solution for improving the management of hypertension and heart failure, potentially enhancing patient adherence and overall treatment outcomes.

References

FRONTLINE MEDICAL SCIENCES AND PHARMACEUTICAL JOURNAL
(ISSN – 2752-6712)
VOLUME 04 ISSUE 08 Pages: 13-22
OCLC – 1272874727
Crossref doi Google Scholar WorldCat MENDELEY
FRONTLINE JOURNALS
Publisher: Frontline Journals

1. Arya, A., Chandra, A., Sharma, V., & Pathak, K. (2010). "Fast Dissolving Oral Films: An Innovative Drug Delivery System and Dosage Form." International Journal of Chemical Technology Research, 2, 576-583.
2. Choudhary, D. R., Patel, V. A., & Kundawala, A. J. (2011). "Formulation and Evaluation of Quick Dissolving Film of Levocetirizine Dihydrochloride." International Journal of Pharmaceutical Technology, 3(1), 1740-1749.
3. Dixit, R. P., & Puthli, S. P. (2009). "Oral Strip Technology: Overview and Future Potential."
4. Journal of Controlled Release, 139, 94-107.
5. Jain, C. P., & Naruka, P. S. (2009). "Formulation and Evaluation of Fast Dissolving Tablets of Valsartan." International Journal of Pharmaceutical Sciences, 1(1), July-September.
6. Kunte, S., & Tandale, P. (2010). "Fast Dissolving Strips: A Novel Approach for the Delivery of Verapamil." Journal of Pharmacy and Bioallied Sciences, 2(4), 325-328.
7. Mishra, R., & Amin, A. (2011). "Formulation and Characterization of Rapidly Dissolving Films of Cetirizine Hydrochloride Using Pullulan as a Film Forming Agent." Indian Journal of Pharmaceutical Education and Research, 45(1), 75-76.
8. Patil, S. B., & Shahi, S. R. (2009). "Formulation and Evaluation of Quick Dispersible Tablet of Olanzapine." International Journal of Pharmaceutical Research and Development, 7, 30- 34.
9. Raju, S., Reddy, P., & Kumar, V. (2011). "Flash Release Oral Films of Metoclopramide Hydrochloride for Pediatric Use: Formulation and In-vitro Evaluation." Journal of Chemical and Pharmaceutical Research, 3(4), 636-646.
10. Saini, S., Nanda, A., & Dhari, J. (2011). "Formulation, Development & Evaluation of Oral Fast Dissolving Anti-allergic Film of Levocetirizine Dihydrochloride." Journal of Pharmaceutical Sciences and Research, 3(7), 1322-1325.